Our lab previously established that metformin, a first-line type two diabetes treatment, activates the Nrf2 pathway and improves post-stroke recovery. Metformin’s brain permeability value and potential interaction with blood–brain barrier (BBB) uptake and efflux transporters are currently unknown. Metformin has been shown to be a substrate of organic cationic transporters (Octs) in the liver and kidneys. Brain endothelial cells at the BBB have been shown to express Octs; thus, we hypothesize that metformin uses Octs for its transport across the BBB. We used a co-culture model of brain endothelial cells and primary astrocytes as an in vitro BBB model to conduct permeability studies during normoxia and hypoxia using oxygen–glucose deprivation (OGD) conditions. Metformin was quantified using a highly sensitive LC-MS/MS method. We further checked Octs protein expression using Western blot analysis. Lastly, we completed a plasma glycoprotein (P-GP) efflux assay. Our results showed that metformin is a highly permeable molecule, uses Oct1 for its transport, and does not interact with P-GP. During OGD, we found alterations in Oct1 expression and increased permeability for metformin. Additionally, we showed that selective transport is a key determinant of metformin’s permeability during OGD, thus, providing a novel target for improving ischemic drug delivery.
6 October 2022 in Cellular and Molecular Neurobiology
The blood‐brain barrier (BBB) is a selectively permeable barrier made up of tight junctions formed by endothelial cells that separates the circulating blood from the brain extracellular fluid. The primary function of the BBB is to limit the movement of xenobiotics from the blood to the brain. In the event of an ischemic stroke, the BBB opens allowing water and ions to enter the brain, leading to excitotoxicity and edema formation. Targeting such opening of the barrier following ischemic stroke has become a focus in current stroke studies. It has been shown that the Wnt/b‐catenin pathway is important for barrier formation during embryonic development, therefore, we hypothesized that activation of this pathway following ischemic stroke would attenuate barrier dysfunction. Brain microvascular endothelial cells (BMECs) derived from iPSCs were cultured and placed in ischemic stress for 6hrs, followed by an 18‐hour period of re‐oxygenation. Wnt small molecule activators (CHIR99021 and SB‐216763) and inhibitors (XAV939, IWP‐4, IWR‐1) were introduced at different time points of differentiation, during ischemia, and during re‐oxygenation. Transendothelial Electrical Resistance (TEER) and permeability were performed to assess barrier integrity following re‐oxygenation. For in vivo studies, C57BL mice were subjected to one‐hour ischemia by MCAO. At the time of re‐oxygenation, mice were dosed with CHIR99021 (IP; 30mg/kg). 24‐hours post‐MCAO, TTC staining on brains was performed to determine infarct size and edema ratio. The results of the in vitro studies have shown that activation of the Wnt pathway during re‐oxygenation results in increased barrier function, suggesting that the Wnt pathway is a potential target for post‐stroke therapy. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Glioblastoma (GBM) is one of the most aggressive and treatment-resistant cancers, shaped by a tumor microenvironment (TME) that is both metabolically demanding and strongly immunosuppressive. GBM relies heavily on fatty acid (FA) metabolism to sustain growth of rapidly dividing tumor cells and survive metabolic stress. GBM cells enhance lipid uptake, activate sterol regulatory element-binding protein 1 (SREBP-1)-driven lipogenesis, store excess lipids in droplets to prevent toxicity, and depend on fatty acid oxidation (FAO) to generate adenosine triphosphate (ATP) and maintain redox balance, particularly under nutrient-limited conditions. GBM TME is also consistently enriched with regulatory T cells (Tregs), which maintain suppressive activity despite the nutrient restrictions that impair effector T cells (Teffs). In hypoxia and nutrient limitation within the TME, Tregs can adapt by using FAO, lactate oxidation, and OXPHOS, supported by forkhead box P3 (Foxp3)-dependent metabolic programming, cluster of differentiation 36 (CD36)-mediated FA uptake, and hypoxia-related signals. At the same time, programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling reduces glycolytic activity in Teffs and contributes to metabolic dysfunction, while also supporting the stability of oxidative metabolism in Tregs. Evidence from pre-clinical and clinical studies suggests a possible association between Treg enrichment in GBM and reduced responsiveness to immune checkpoint inhibitors (ICIs), although this relationship is not yet fully defined. Overall, current findings point to FA metabolism as a shared metabolic axis that supports both tumor progression and Treg-mediated immune resistance. Targeting lipid-driven pathways may offer an opportunity to disrupt these advantages and improve the effectiveness of existing immunotherapies for GBM.